Inflammatory bowel disease (IBD) is a chronic, immunologically mediated disorder of the gastrointestinal tract in which tissue damage and sustained inflammation lead to long-term dysfunction of the gastrointestinal tract.
Data on the poly(ADP-ribose) glycohydrolase (PARG) inhibitor SYX-3759, being investigated for the treatment of homologous recombination deficient (HRD) malignancies, were recently discussed by researchers from Hangzhou Synrx Therapeutics Technology Co. Ltd.
Researchers from Hangzhou Polymed Biopharmaceuticals Inc. have reported the discovery and preclinical evaluation of HPB-092, an FMS-like tyrosine kinase 3 (FLT3) and interleukin-1 receptor-associated kinase 4 (IRAK-4) dual inhibitor, being developed for the treatment of acute myeloid leukemia (AML).
Researchers from Dong Wha Pharmaceutical Co. Ltd. presented preclinical evaluation of a newly discovered histone-lysine N-methyltransferase EZH1/2 dual inhibitor, DW-91170, being developed for the treatment of lymphoma.
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) pathway comprises four JAK kinases and seven STAT transcription factors. Among the latter, STAT3 is the best-known oncogene and its essential role in normal tissue makes its complete blockage useless for treatment due to severe side effects.
Macrophages are specialized immune cells that can either stimulate or inhibit inflammation. Studies in mice suggest that phosphoinositide 3-kinase γ (PI3Kγ), a key mediator in macrophage signaling pathways predominantly expressed in myeloid cells, may promote immune suppression both in inflammation and in the tumor microenvironment.
RSS
